On Thursday, Feb. 1, Boston Scientific
- Fourth-quarter sales grew 34.1% to $2.1 billion as the company acquired rival Guidant and Advanced Bionics.
- Total diluted earnings fell 52.5% for the quarter as merger charges and other costs reduced bottom-line results. On an adjusted basis, for the year the company detailed it earned $1.12 per share rather than the reported loss of $2.81.
- Management offered first-quarter guidance of $2 billion-$2.1 billion in sales and $0.15-$0.21 in earnings, excluding special charges and certain other expenses.
(Figures in millions, except per-share data)
Income Statement Highlights
Avg. Est. |
Q4 2006 |
Q4 2005 |
Change |
|
---|---|---|---|---|
Sales |
$2,070 |
$2,065 |
$1,540 |
34.1% |
Net Profit |
-- |
$277 |
$334 |
(17.1%) |
EPS |
$0.11 |
$0.19 |
$0.40 |
(52.5%) |
Diluted Shares |
1,494 |
830 |
80.0% |
Get back to basics with a look at the income statement.
Margin Checkup
Q4 2006 |
Q4 2005 |
Change* |
|
---|---|---|---|
Gross Margin |
74.53% |
77.79% |
(3.26) |
Operating Margin |
13.75% |
30.19% |
(16.44) |
Net Margin |
13.41% |
21.69% |
(8.28) |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
Assets |
Q4 2006 |
Q4 2005 |
Change |
---|---|---|---|
Cash + ST Invest. |
$1,668 |
$848 |
96.7% |
Accounts Rec. |
$1,424 |
$932 |
52.8% |
Inventory |
$749 |
$418 |
79.2% |
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
---|---|---|---|
Accounts Payable |
$2,067 |
$1,229 |
68.2% |
Long-Term Debt |
$8,895 |
$1,864 |
377.2% |
Learn the ways of the balance sheet.
Cash Flow Highlights
Fools will have to wait until the 10-K is filed for juicy cash flow details.
Find out why Fools always follow the money.
Comparable companies:
-
Medtronic
(NYSE:MDT) -
St. Jude
(NYSE:STJ) -
Johnson & Johnson
(NYSE:JNJ) -
Abbott Labs
(NYSE:ABT)
Related Foolishness:
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
Johnson & Johnson is an Income Investor recommendation. To find out why, take the newsletter for a free 30-day trial.
Fool contributor Ryan Fuhrmann has no financial interest in any company mentioned. Feel free to email him with feedback or to discuss any companies mentioned further. The Fool has an ironclad disclosure policy.